Breast cancer is one of the commonest cancers among women. Conventional therapies cause adverse side effects in patients. Cytokine immunotherapy such as 
Conventional treatments such as chemotherapy and surgery have successfully increased breast cancer patients' life span (Isakoff 2010) , however, they, at the same time, cause tremendous adverse side effects in patients such as immunosuppression, congestive heart failure, leukemia (Pan et al. 2014) , emotional breakdown and depression due to physical changes (Arroyo & Lopez 2010) . Owing to the shortcomings of currently available treatments for breast cancers, Stagg & Allard (2013) suggested that cytokine immunotherapy could be eligible alternative for treating breast cancer patients with negligible or minimal adverse effects. Cytokines can inhibit progression of cancer cells by augmenting anticancer immunity meanwhile promoting production of anti-angiogenic proteins such as IFN-γ and monokines (Shimizu et al. 2006) . Such encouraging effects have been proven in a few clinical trials using aldesleukin (Interleukin 2, IL-2), protein CSPG4 and nY-ESO-1 (Ademuyiwa et al. 2012; Wang et al. 2010; Roberti et al. 2011 ) on breast cancer patients. Although these cytokines possessed effective anti-breast cancer activities, some recipients still experienced side effects such as fever, low platelet and white blood cells counts (Rosenberg et al. 2011; Sharma et al. 2011) . to help address the concern, the use of interleukin-27 (IL-27) that has been proven to prohibit colon cancer and myeloma growth was proposed (ho et al. 2009 ). IL-27 treatment has triggered very minimal side effects in preclinical trials using rat models (Yoshimoto et al. 2015) . IL-27 is a heterodimeric cytokine that is composed of two protein subunits, Epstein-Barr virus gen induced-3 (EBVI-3) and p28 (Pflanz et al. 2002) . Zarghi & Arfaei (2011) demonstrated that IL-27 was able to undermine the expression of anti-apoptotic factors such as COX-2 and PGE-2 in cancer cells. Besides, IL-27 also upregulates the protein expression level of interferon gamma (IFN-γ) which in turn triggers the production of apoptotic proteins such as caspases (Ruiz-Ruiz, Muñoz-Pinedo & López-Rivas 2000) that induce programmed cancer cell death.
Despite the proven anti-angiogenic effects and enhancement of anticancer immunity by IL-27, explicit regulatory effects of IL-27 on the expression of apoptotic and anti-apoptotic genes particularly in breast cancers are barely available. In view of this, the current study aimed to investigate the cytotoxicity, regulation of apoptotic and anti-apoptotic gene expression by IL-27 in MCF-7 and MDA-MB-231 breast cancer cell lines. the results indicated that IL-27 was able to obstruct breast cancer cell growth and regulate the expression of apoptotic and antiapoptotic genes, hence, a potential candidate for cytokine immunotherapy in treating breast cancers.
MAtERIALS AnD MEthODS

CELLS AnD IL-27
Breast cancer cell lines, MDA-MB-231 and MCF-7 and non-cancerous breast cell line, 184b5 were purchased from American type Culture Collection (AtCC) and were maintained in MEM medium (Sigma-Alrich, St. Louis, uSA) supplemented with 10% (v/v) fetal bovine serum (SigmaAldrich, St Louis, uSA) and 50 μg/ml PenStrep antibiotics (Sigma-Aldrich, St Louis, uSA). Cells were grown at 37°C in a 5% CO 2 incubator. Interleukin-27 (IL-27) (SigmaAldrich, St. Louis, uSA) was prepared as 10 µg/ml stock with nuclease-free water and then serially diluted to 50-500 ng/ml with MEM medium.
CYtOtOXICItY OF IL-27 In nOn-CAnCEROuS AnD
CAnCEROuS BREASt CELL LInES
Cytotoxicity of IL-27 in 184b5, MDA-MB-231 and MCF-7 cells was determined by using MtS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium, inner salt] assay kit (Celltiter 96® AQueous One Solution Cell Proliferation Assay) (Sigma-Aldrich, St Louis, uSA). Cells (2 × 10 5 cells/ml) were cultured on 96-well plates and incubated overnight at 37°C under 5% CO 2 . Cells were then washed three times with PBS and 50-500 ng/ml of IL-27 (Canale et al. 2011 ) was added to the cells in triplicate. non-treated cells were prepared as negative control. IL-27 treatment was carried out for 24, 48, and 72 h. At each designated time point, the plate was collected and media was removed. Cells were washed with PBS and 100 μl fresh MEM medium was added to the cells. About 20 μl of Celltiter 96® AQueous One Solution reagent was added into each well and the cells were further incubated for 3 h at 37°C under 5% CO 2 . the plate was read at 570 nm. Doseresponse curve was conducted by using the absorbance readings. the value of 50% inhibitory concentration (IC 50 ) of IL-27 was derived from the curve.
ISOLAtIOn OF tOtAL RnA to allow collection of cells at larger number, MDA-MB-231 and MCF-7 cells (3 × 10 5 cells/ml) were cultured on a 6-well plate at 37°C under 5% CO 2 until 80% confluency was achieved. MCF-7 and MDA-MB-231 cells were treated with IL-27 at IC 50 in duplicate for 48 and 72 h, respectively. After the treatment, the total RnA was extracted from the samples by using tRIzol RnA reagent (Invitrogen, new York, uSA) as described in tan, hassan & Yap (2016) . the extracted total RnA (250 ng) was used to generate cDnA using M-MLV reverse transcriptase (Promega Inc, Madison, uSA Figure 1a ). MCF-7 breast cancer cells exhibited 100% viability while 184b5 breast cells remained growing in the range of 80 to 100%. Although slightly affected at higher concentrations of IL-27, MDA-MB-231 cells was still able to maintain at least 90% viability. Figure 1 (b) shows the effects of IL-27 treatment on the viability of the cells for 48 h. the viability of 184b5 and MDA-MB-231 remained relatively stable and unchanged which cell viability was at least 80%. however, a much lower viability was observed in MCF-7 breast cancer cell line especially when treated with 500 ng/ml of IL-27. the cell viability was only retained at 10%. Based on the curve, IC 50 of IL-27 in MCF-7 was determined at 442 ng/ml.
As IL-27 treatment progressed to 72 h, none of the MCF-7 cells survived the treatment while 184b5 cells still did not exhibit any signs of toxicity from the treatment ( Figure 1C ). For MDA-MB-231 cells treated with IL-27 at 200-500 ng/ml, cell viability declined gradually in a concentration-dependent pattern. the cell viability was less than 50% after being treated with IL-27 at 500 ng/ml for 72 h, hence the IC 50 of 457 ng/ml. REGuLAtIOn OF APOPtOtIC AnD AntI-APOPtOtIC GEnE EXPRESSIOn BY IL-27 In MCF-7 AnD MDA-MB-231 BREASt CAnCER CELL LInES MCF-7 (442 ng/ml) and MDA-MB-231 (457 ng/ml) cells were first treated with IL-27 at IC 50 for 48 and 72 h, respectively. the effects of IL-27 treatment on the expression levels of apoptotic and anti-apoptotic genes were analyzed using PCR. As shown in Figure 2A and 2B, IL-27 treatment upregulated gene expression of TRAIL, caspase-3 and caspase-8 in both MCF-7 and MDA-MB-231 cell lines. nevertheless, treatment with IL-27 was unable to upregulate the expression of FAS and FADD genes in the breast cancer cells.
Regulation of anti-apoptotic gene expression in MCF-7 and MDA-MB-231 breast cancer cells by IL-27 was also investigated in this study. In MCF-7 cells, expression of AKT and BCL-2 genes decreased following IL-27 treatment ( Figure 2C) . however, the interleukin treatment seemed to slightly increase the expression of AKT and BCL-2 genes in MDA-MB-231 cells ( Figure 2D ). COX-2 gene was expressed minimally by untreated MDA-MB-231 cells. the gene expression was then suppressed by a 72-h treatment with IL-27 ( Figure 2D ). unlike that observed in untreated and treated MDA-MB-231 cells, the COX-2 gene expression was not detected in both untreated and treated MCF-7 cells. Regulation of apoptotic and anti-apoptotic gene expression by IL-27 in breast cancer cells was further estimated by comparing the expression levels of those genes with the expression level of the housekeeping gene, GADPH. Based on Figure 3A , IL-27 treatment successfully upregulated the gene expression levels of TRAIL (0.7), caspase-3 (0.7) and caspase-8 (0.6) significantly (p < 0.05) in treated MCF-7 cells compared to that of nontreated samples (undetectable). In MDA-MB-231 cells ( Figure 3B ), IL-27 treatment had managed to increase the relative gene expression levels of caspase-3 (0.3 to 1.6) and caspase-8 (undetectable to 1.8) significantly (p < 0.05). the relative gene expression level of TRAIL in IL-27-treated MDA-MB-231 cells also showed some level of increment (almost 1.2), however, the upregulation was not statistically significant enough (p > 0.05) when compared with that of non-treated cells.
As shown in Figure 3C , the relative gene expression level of AKT in MCF-7 cells declined from 0.7 to 0.6 after being treated with IL-27. the reduction was not statistically significant (p > 0.05). Similarly, the relative gene expression level of BCL-2 in MCF-7 cells was also not significantly (p > 0.05) affected by IL-27 treatment. the relative gene expression level decreased from 0.4 to 0.3.
It is noteworthy that IL-27 treatment had, on the other hand, upregulated (p < 0.05) the relative expression levels of AKT and BCL-2 in MDA-MB-231 cells ( Figure 3D ). unlike the AKT and BCL-2 genes, COX-2 gene expression was somewhat inhibited significantly (p < 0.05) by IL-27 in MDA-MB-231 cells.
DISCuSSIOn
Breast cancer is the one of most severe cancers affecting women globally (WhO 2014). According to statistics by the International Agency for Research on Cancer, Malaysia has 38.7% breast cancer incidence rate with 5410 new cases in 2012 alone (Yip, Pathy & teo 2014) . norsaadah et al. (2005) explained that the increased risk of breast cancers among Malaysian women is mainly due to lifestyle and hereditary genetic factors. Chemotherapy, radiotherapy and mastectomy have long been used in breast cancer treatments (Wijayahadi et al. 2007) . Although effective, these therapies nevertheless cause adverse side effects such as ovarian failure (tiong et al. 2014 ) and neutropenia (Phua et al. 2012) strategy for breast cancer treatment. Immunotherapy stimulates specific anticancer immune cells that destroy and inhibit cancer cell growth without affecting the normal cells (Pflanz et al. 2002) . In recent years, anticancer effects of cytokines have been widely studied as these signaling peptides are believed to be useful for immunotherapy especially in terms of enhancing anticancer immunity and, at the same time, activate immune responses that prohibit cancer cells from proliferating uncontrollably (Lee & Margolin 2011) . As a member of cytokines with potent anticancer effects, IL-27 has been shown to inhibit anti-angiogenesis which in turns induces cancer cell death without causing inflammation and toxicity to normal cells (Lucas et al. 2003) . For this reason, cytotoxicity, regulation of apoptotic and anti-apoptotic gene expression by IL-27 in breast cancers were studied using MDA-MB-231 and MCF-7 breast cancer cell lines in this study. MCF-7 breast cancer cell line represented the major type (invasive ductal cancer, IDC) of breast cancers that is commonly found in breast cancer patients. IDC accounts for almost 80% of breast cancer incidences (Martinez & Azzopardi 1979) . MDA-MB-231, on the other hand, represented the aggressive, metastatic breast cancer that is responsible for approximately 20% of breast cancer cases (tommiska et al. 2007) .
Since there were no empirical data on cytotoxicity of IL-27 in non-cancerous and cancerous breast cell lines, the cytotoxicity assay was first performed at the concentration range of 50-500 ng/ml in order to determine the IC 50 of IL-27 in both non-cancerous and cancerous breast cell lines. the concentration range was chosen according to Canale et al. (2011) that showed any IL-27 concentrations below 100 ng/ml did not significantly inhibit the growth of leukemic cells in acute B-lymphoma for 24 to 48 h of treatment. Even with increasing concentrations, anti-leukemic effects of IL-27 could only be observed at 200 ng/ml after 72 h of treatment. In this light, the concentration range of IL-27 was set at 50-500 ng/ml while IL-27 treatment was performed from 24-72 h in this study. the results showed that IL-27 treatment did not exert adverse toxic effects on non-cancerous breast cells, 184b5 but managed to inhibit more than 50% of MCF-7 and MDA-MB-231 breast cancer cell growth after 48-and 72-h treatments, respectively. this finding is in line with Dong et al. (2016) in which IL-27 was shown to be able to exert significant cytotoxicity to A549 lung carcinoma cells after 48 h of treatment. Besides, the cytotoxicity of IL-27 in both cancer cell lines also increased in a concentration-dependent manner. this observation is similar to that reported by Cocco et al. (2010) . Compared to MCF-7 cells, IL-27 required longer duration in triggering MDA-MB-231 cell death. this is most likely because MDA-MB-231 is highly aggressive and resistant to treatment due to its triple-negative characteristics (Di Carlo et al. 2014) . It was found that highly anticancer-resistant cancers would require treatment duration as long as 120 h for IL-27 to exert it cytotoxic effects on the cancer cells. Chiba et al. (2013) demonstrated that IL-27 treatment was able to inhibit melanoma growth by regulating tRAIL pathway. upregulation of TRAIL gene in both MCF-7 and MDA-MB-231 cells by IL-27 in this study correlates well with findings in that report. By enhancing tRAIL expression in cancer cells, apoptosis occurs and results in cancer cell death through activation of caspases such as caspase-3 and -8 (Wang & El Deiry 2003) . Caspase-3 and -8 gene expression levels in breast cancer cells were found increased by IL-27 treatment in this study. this result supports findings by tang, Lahti and Kidd (2000) in which caspase-3 activation was an important key for the generation of functional caspase-8 in MCF-7 cells. In view of this, together with upregulation of tRAIL gene expression, it is probable that IL-27 induced cell death in MCF-7 and MDA-MB-231 via tRAIL/caspase 3/caspase 8 pathway.
Expression of FAS and FADD genes was not affected by IL-27 treatment in both of the breast cancer cell lines. Previous findings showed that MCF-7 and MDA-MB-231 breast cancer cells were less responsive to FAS and FADD gene expression even when treated with anti-cancer agents such as IFN-γ at 10 times higher concentration (Keane et al. 1996; Mullauer et al. 2000) . Furthermore, Day, huang & Safa (2008) IL-27 treatment slightly lowered AKT and BCL-2 gene expression in MCF-7 cells in this study. Reduction of AKT and BCL-2 gene expression had been shown to speed up melanoma cell death through anti-angiogenesis (Cocco et al. 2010 ) and apoptosis in cancer cells by release of cytochrome-c (Cory, huang & Adams 2003) . Youle & Strasser (2008) also found that it is important for breast cancer cells to maintain high BCL-2 level in order to sustain their growth. therefore, a slight reduction of BCL-2 level could wreak dramatic change such as cell death in breast cancer cells as seen in this study.
unlike MCF-7 breast cancer cells, the gene expression levels of AKT and BCL-2 were somehow upregulated by IL-27 in MDA-MB-231 cells. A similar observation was reported by Chen et al. (2001) . In the report, it was clearly demonstrated that even if the anti-apoptotic genes were upregulated in cancer cells, the relatively high expression level of TRAIL gene was able to block their anti-apoptotic activities hence cancer cell death. Besides, although often regarded as an anti-apoptotic gene, BCL-2 is also responsible for the activation of certain apoptotic molecules such as BAX and BAD, therefore leading to cancer cell death (Delbridge et al. 2016 ) as observed in IL-27 treated MDA-MB-231 cells in this study. It is noteworthy that further laboratory investigations are required to authenticate these speculations rigorously. 
COnCLuSIOn
Although this study presents preliminary evidence on cytotoxicity of IL-27 in non-cancerous and cancerous breast cell lines, it offers vital information on the potential use of IL-27 in treating breast cancers without causing much side effects to patients. Early evidence describing how IL-27 regulates apoptotic and anti-apoptotic gene expression in breast cancer cells, on the other hand, provide important insight for further laboratory investigations so IL-27 can be used more specifically and precisely as a potential anti-breast cancer cytokine. Conclusively, IL-27 holds promise as a potential interleukin candidate in cytokine immunotherapy for breast cancers. 
